Subtopic Deep Dive
RAS Signaling in Cardiac Fibrosis
Research Guide
What is RAS Signaling in Cardiac Fibrosis?
RAS Signaling in Cardiac Fibrosis examines angiotensin II-driven pathways that promote myocardial extracellular matrix deposition and fibrosis in hypertensive heart disease.
Angiotensin II activates TGF-β and aldosterone signaling to induce fibroblast proliferation and collagen synthesis in the myocardium (Berk et al., 2007). ACE2 counteracts this by converting angiotensin II to angiotensin 1-7, reducing fibrotic responses (Donoghue et al., 2000). Over 50 papers detail these mechanisms, with key works cited over 3000 times.
Why It Matters
RAS inhibitors like ACEi and ARBs prevent diastolic dysfunction and heart failure with preserved ejection fraction by blocking angiotensin II-induced fibrosis (Liu et al., 1997). In hypertensive heart disease, ECM remodeling drives systolic and diastolic failure, affecting millions globally (Berk et al., 2007). Targeting NADPH oxidase activation by angiotensin II reduces vascular superoxide and fibrosis progression (Rajagopalan et al., 1996).
Key Research Challenges
Heterogeneous Fibrosis Models
Animal models of angiotensin II infusion show variable fibrosis due to strain differences and dosing (Rajagopalan et al., 1996). Human translation fails as biopsy data is limited. Berk et al. (2007) highlight inconsistent ECM markers across hypertensive patients.
ACE2 Degradation Pathways
ACE2 loss exacerbates fibrosis but its regulation by inflammation remains unclear (Donoghue et al., 2000). Angiotensin 1-7 protective effects vary by tissue. Tikellis and Thomas (2012) note incomplete understanding of ACE2 in cardiac contexts.
Therapeutic Resistance Mechanisms
RAS blockers improve remodeling but fail in advanced fibrosis due to aldosterone escape (Liu et al., 1997). NADPH oxidase persistence limits benefits (Rajagopalan et al., 1996). Intengan and Schiffrin (2001) describe persistent vascular changes post-treatment.
Essential Papers
A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9
Mary Donoghue, F. Hsieh, Elizabeth Baronas et al. · 2000 · Circulation Research · 3.1K citations
Abstract —ACE2, the first known human homologue of angiotensin-converting enzyme (ACE), was identified from 5′ sequencing of a human heart failure ventricle cDNA library. ACE2 has an apparent signa...
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.
Sanjay Rajagopalan, Stephan Kurz, Thomas Münzel et al. · 1996 · Journal of Clinical Investigation · 2.4K citations
We tested the hypothesis that angiotensin II-induced hypertension is associated with an increase in vascular .O2- production, and characterized the oxidase involved in this process. Infusion of ang...
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
Muthiah Vaduganathan, Orly Vardeny, Thomas Michel et al. · 2020 · New England Journal of Medicine · 2.1K citations
RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain. The authors hy...
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Paolo Verdecchia, Claudio Cavallini, Antonio Spanevello et al. · 2020 · European Journal of Internal Medicine · 1.3K citations
Vascular Remodeling in Hypertension
Hope D. Intengan, Ernesto L. Schiffrin · 2001 · Hypertension · 960 citations
Abstract — — Remodeling of large and small arteries contributes to the development and complications of hypertension. The focus of this review is some of the mechanisms involved in the remodeling o...
ECM remodeling in hypertensive heart disease
Bradford C. Berk, Keigi Fujiwara, Stéphanie Lehoux · 2007 · Journal of Clinical Investigation · 890 citations
Hypertensive heart disease (HHD) occurs in patients that clinically have both diastolic and systolic heart failure and will soon become the most common cause of heart failure. Two key aspects of he...
Angiotensin II revisited: new roles in inflammation, immunology and aging
Ariela Benigni, Paola Cassis, Giuseppe Remuzzi · 2010 · EMBO Molecular Medicine · 736 citations
Reading Guide
Foundational Papers
Start with Donoghue et al. (2000, 3119 citations) for ACE2 discovery in heart failure ventricles, then Rajagopalan et al. (1996, 2441 citations) for angiotensin II oxidase mechanisms, and Berk et al. (2007) for ECM in hypertensive disease.
Recent Advances
Vaduganathan et al. (2020, 2143 citations) on RAAS inhibitors in Covid-19 links to ACE2; Verdecchia et al. (2020, 1260 citations) on ACE2 deficiency and infection risks.
Core Methods
Ang II infusion in rats (Rajagopalan et al., 1996); ACE2 expression via cDNA sequencing (Donoghue et al., 2000); fibrosis quantification by picrosirius red and echocardiography (Berk et al., 2007).
How PapersFlow Helps You Research RAS Signaling in Cardiac Fibrosis
Discover & Search
Research Agent uses searchPapers('RAS signaling cardiac fibrosis angiotensin II') to retrieve 250+ OpenAlex papers, then citationGraph on Donoghue et al. (2000, 3119 citations) maps ACE2 influence networks, and findSimilarPapers uncovers related ECM studies like Berk et al. (2007). exaSearch refines for 'TGF-β aldosterone cardiac fibrosis' yielding precise hits.
Analyze & Verify
Analysis Agent applies readPaperContent on Rajagopalan et al. (1996) to extract NADPH oxidase data, verifyResponse with CoVe checks claims against 10 similar papers, and runPythonAnalysis plots superoxide levels from extracted datasets using matplotlib. GRADE grading scores evidence strength for therapeutic claims in Liu et al. (1997).
Synthesize & Write
Synthesis Agent detects gaps in ACE2-fibrosis links across papers, flags contradictions between vascular (Intengan and Schiffrin, 2001) and cardiac models (Berk et al., 2007), and generates exportMermaid diagrams of RAS pathways. Writing Agent uses latexEditText for manuscript sections, latexSyncCitations for 20+ references, and latexCompile for PDF review.
Use Cases
"Extract and plot NADPH oxidase activity data from angiotensin II hypertension papers"
Research Agent → searchPapers('angiotensin II NADPH oxidase cardiac') → Analysis Agent → readPaperContent(Rajagopalan 1996) → runPythonAnalysis(pandas plot superoxide vs dose) → matplotlib figure of dose-response curves.
"Write LaTeX review on ACE2 role in cardiac fibrosis with citations"
Synthesis Agent → gap detection(ACE2 fibrosis) → Writing Agent → latexEditText('ACE2 counteracts Ang II fibrosis') → latexSyncCitations(Donoghue 2000, Tikellis 2012) → latexCompile → camera-ready PDF section.
"Find code for RAS signaling simulation models in fibrosis papers"
Research Agent → searchPapers('RAS cardiac fibrosis simulation model') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → downloadable Python model for angiotensin II-TGF-β pathway.
Automated Workflows
Deep Research workflow scans 50+ RAS fibrosis papers via searchPapers → citationGraph → structured report with GRADE scores on ACE2 interventions (Donoghue et al., 2000). DeepScan applies 7-step CoVe analysis to Berk et al. (2007) ECM data with runPythonAnalysis for matrix stats. Theorizer generates hypotheses on aldosterone escape from Liu et al. (1997) and Rajagopalan et al. (1996).
Frequently Asked Questions
What defines RAS signaling in cardiac fibrosis?
Angiotensin II activates AT1 receptors, inducing TGF-β and aldosterone to drive fibroblast collagen deposition (Berk et al., 2007).
What are key methods in this subtopic?
Rat models use angiotensin II infusion (0.7 mg/kg/d) to measure superoxide via NADH/NADPH oxidase and fibrosis by Masson's trichrome (Rajagopalan et al., 1996).
What are seminal papers?
Donoghue et al. (2000, 3119 citations) discovered ACE2 from heart failure cDNA; Berk et al. (2007, 890 citations) detailed ECM remodeling in hypertensive heart disease.
What open problems exist?
ACE2 regulation in human fibrosis and resistance to RAS inhibitors in advanced stages remain unresolved (Tikellis and Thomas, 2012; Liu et al., 1997).
Research Renin-Angiotensin System Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching RAS Signaling in Cardiac Fibrosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Renin-Angiotensin System Studies Research Guide